Original Article

You have full text access to this OnlineOpen article

Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas†

  1. Roger J. Packer M.D.1,2,3,‡,*,
  2. Mark Krailo Ph.D.4,5,
  3. Minesh Mehta M.D.6,
  4. Katherine Warren M.D.7,
  5. Jeffrey Allen M.D.8,
  6. Regina Jakacki M.D.9,
  7. Judith G. Villablanca M.D.10,
  8. Akiko Chiba B.S.11,
  9. Gregory Reaman M.D.3,5,11

Article first published online: 2 AUG 2005

DOI: 10.1002/cncr.21301

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1281–1287, 15 September 2005

Additional Information

How to Cite

Packer, R. J., Krailo, M., Mehta, M., Warren, K., Allen, J., Jakacki, R., Villablanca, J. G., Chiba, A. and Reaman, G. (2005), Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer, 104: 1281–1287. doi: 10.1002/cncr.21301

Author Information

  1. 1

    Division of Neurology, Children's National Medical Center, Washington, DC

  2. 2

    Department of Neurology, The George Washington University, Washington, District of Columbia

  3. 3

    Department of Pediatrics, The George Washington University, Washington, District of Columbia

  4. 4

    University of Southern California, Keck School of Medicine, Los Angeles, California

  5. 5

    The Children's Oncology Group, Arcadia, California

  6. 6

    Department of Radiation Oncology, The University of Wisconsin Medical Center, Madison, Wisconsin

  7. 7

    Division of Neuro-Oncology Branch, The National Cancer Institute, Bethesda, Maryland

  8. 8

    Division of Oncology, New York University, New York, New York

  9. 9

    Division of Oncology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

  10. 10

    Division of Oncology, Children's Hospital of Los Angeles, Los Angeles, California

  11. 11

    Division of Hematology/Oncology, Children's National Medical Center, Washington, District of Columbia

  1. ‡

    Fax: (202) 884-5226

*Division of Neurology, Children's National Medical Center; 111 Michigan Avenue, NW, Washington, DC 20010

  1. †

    Presented, in part, at the 33rd Annual Meeting of the Child Neurology Society, Ottawa, Canada, October 15, 2004.

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 2 AUG 2005
  3. Manuscript Accepted: 25 MAR 2005
  4. Manuscript Revised: 22 FEB 2005
  5. Manuscript Received: 29 NOV 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (107K)

REFERENCES

  • 1
    Jenkin RDT, Boesel C, Ertel E, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. J Neurosurg. 1987; 66: 227–233.
  • 2
    Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies in the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1992; 33: 1026–1030.
  • 3
    Packer RJ, Boyett JM, Zimmerman RA, et al. Brain stem gliomas of childhood: outcome after treatment with 7800 cGy of hyperfractionated radiotherapy, a Children's Cancer Group phase I/II trial. Cancer. 1994; 74: 1827–1834.
    Direct Link:
  • 4
    Fu KK, Phillips TL. Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am. 1991; 5: 737–749.
  • 5
    Friedman HS, Krischer PB, Oakes WG, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992; 10: 249–256.
  • 6
    Allen J, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987; 5: 459–463.
  • 7
    Schwachoffer JHM, Crookjmans RPM, Hoogenhout J, Kal HB, Theeuwes AGM. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence. Int J Radiat Oncol Biol Phys. 1991; 20: 1235–1241.
  • 8
    Schaake-Koning C, van cen Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992; 326: 524–530.
  • 9
    Zinke H, Mockel B, Frey A, et al. Blood-brain barrier: a molecular approach to its structural and functional characterization. Prog Brain Res. 1992; 91: 103–116.
  • 10
    Rapoport SI. Osmotic opening of the blood-brain barrier. Ann Neurol. 1988; 24: 677–684.
    Direct Link:
  • 11
    Regoli D, Gobeil F, Nguyen QT, et al. Bradykinin receptor types and B2 subtypes. Life Sci. 1994; 55: 735–749.
  • 12
    Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab. 1994; 14: 862–870.
  • 13
    Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol. 1992; 20(Suppl 9): S4–9.
  • 14
    Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog Cereport® increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther. 1994; 271: 229–237.
  • 15
    Elliott PJ, Hayward NJ, Dean RL, et al. Intravenous Cereport® selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 1996; 56: 3998–4005.
  • 16
    Bartus RT, Elliott PJ, Hayward NJ, et al. Permeability of the blood brain barrier by the bradykinin agonist, Cereport®: evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology. 1996; 33: 270–278.
  • 17
    Inamura T, Nomura T, Bartus RT, et al. Intracarotid infusion of Cereport®, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994; 81: 752–758.
  • 18
    Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearng rats by intracarotid infusion of bradykinin analog, Cereport®. Neurosurgery. 1996; 39: 125–134.
  • 19
    Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood-brain barrier: a role for Cereport® in brain tumor therapy. Exp Neurol. 1996; 141: 214–234.
  • 20
    Elliott PJ, Hayward NJ, Dean RL, et al. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, Cereport®. Immunopharmacology. 1996; 33: 205–208.
  • 21
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons, 1980.
  • 22
    Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982; 38: 29–41.
  • 23
    Warnke PC, Blasberg RG, Groothuis DR. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol. 1987; 22: 300–305.
    Direct Link:
  • 24
    Hiesiger EM, Voorhies RM, Basler GA, et al. Opening the blood-brain and blood-tumors barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol. 1986; 19: 50–59.
    Direct Link:
  • 25
    Black KL, Cloughesy T, Huang S-C, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg. 1997; 86: 603–609.
  • 26
    Warren KE, Patel MC, Aikin AA, et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol. 2001; 48: 275–282.
  • 27
    Gregor A, Lind M, Newman H, et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. J Neuro-Oncol. 1999; 44: 137–145.
  • 28
    Van Tassel P, Bruner JM, Maor MH, et al. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. Am J Neuroradiol. 1995; 16: 715–726.
  • 29
    Allen J, Siffert J, DaRosso R, et al. Carboplatin as a radiopotentiating agent for newly diagnosed children with brainstem gliomas [abstract]. Ann Neurol. 1995; 38: 553.
  • 30
    Prados MD, Schold SC Jr., Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology. 2003; 5: 96–103.
View Full Article (HTML) Get PDF (107K)